Drawing for AVAXZIPEN

USPTO serial 79388905

AVAXZIPEN

Reviewed by CopyMark Law Group

Reg. 7656600Status 700Registered
Filing date
Status date
Registration date
Jan 21, 2025
Examiner
PEREZ, STEVEN M
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AVAXZIPEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Rebecca Liebowitz

Rebecca Liebowitz Venable LLPP.O. Box 34385Comberton Road,Washington, DC 20043-9998

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, biopharmaceutical and veterinary preparations and substances for the treatment of and protection against disease; pharmaceutical, biopharmaceutical and veterinary preparations and substances for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders; prophylactic pharmaceutical and veterinary preparations and substances, namely for the treatment of infectious and autoimmune diseases; vaccines; prophylactic vaccines; therapeutic vaccines; vaccine preparations; biological preparations for medical use, namely, mixed biological preparations for the prevention and treatment of infectious and autoimmune diseases; biological, chemical and biochemical reagents for medical use; contraceptive preparations and substances, namely, oral, chemical and parenteral based contraceptivesACTIVE—
010Surgical apparatus and instruments; medical, dental and veterinary apparatus and instruments, namely, injection and infusion devices for administering pharmaceutical, biopharmaceutical and veterinary preparations; drug delivery devices sold empty, namely, injection devices; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations parenterally; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into subcutaneous tissue; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intradermal tissue; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intramuscular tissue; drug delivery devices, namely, drug cassettes sold empty; drug delivery devices, namely medical injectors, needle-free injectors, injectors with needles, all sold empty; drug delivery devices, sold empty, namely, medical injectors, needle-free injectors and parts and fittings therefore; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices for injecting pharmaceutical, biopharmaceutical and veterinary preparations parenterally; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into subcutaneous tissue; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intradermal tissue; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intramuscular tissue; pre-loaded drug cassettes for use in drug delivery devices to contain pharmaceutical and biopharmaceutical preparations and substances for therapeutic, prophylactic and diagnostic use; Structural parts and fittings for all the aforesaid goodsACTIVE—
042Medical and veterinary research and product development services; medical and veterinary device development services; pharmaceutical and biopharmaceutical development services; Product development of pharmaceutical and biopharmaceutical delivery systems; Pharmaceutical and biopharmaceutical product development, namely research and formulation of pharmaceuticals and biopharmaceuticals; research into vaccines; Product testing services for medical and veterinary devices and products; provision of information relating to product development and testing; Consulting services in the field of product development and testingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 5, 2026ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 23, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 5, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 5, 2025FIMPFINAL DISPOSITION PROCESSED—
Jul 26, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 7, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 7, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 22, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 8, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 8, 2025ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 8, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 8, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 21, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 21, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 3, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 3, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 27, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 4, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 25, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 24, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 24, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 16, 2024RFNTREFUSAL PROCESSED BY IB—
Mar 25, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 25, 2024RFRRREFUSAL PROCESSED BY MPU—
Mar 2, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 1, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 12, 2024DOCKASSIGNED TO EXAMINER—
Feb 12, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 9, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance